Joseph F Quinn

List of Publications by Year
in descending order

221 papers	27,014 citations	8181 76 h-index	6836 155 g-index
246 all docs	246 docs citations	246 times ranked	31993 citing authors

#	Article	IF	Citations
1	Blood extracellular vesicles carrying synaptic functionâ€•and brainâ€•related proteins as potential biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 909-923.	0.8	21
2	A Metabolomic Aging Clock Using Human Cerebrospinal Fluid. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 744-754.	3.6	19
3	DCE-MRI of Brain Fluid Barriers: In Vivo Water Cycling at the Human Choroid Plexus. Tissue Barriers, 2022, 10, 1963143.	3.2	6
4	Pharmacokinetics and Pharmacodynamics of Key Components of a Standardized Centella asiatica Product in Cognitively Impaired Older Adults: A Phase 1, Double-Blind, Randomized Clinical Trial. Antioxidants, 2022, 11, 215.	5.1	10
5	The Impact of the hAPP695SW Transgene and Associated Amyloid-Î² Accumulation on Murine Hippocampal Biochemical Pathways. Journal of Alzheimer's Disease, 2022, 85, 1601-1619.	2.6	12
6	Predictive Modeling of Alzheimerâ€™s and Parkinsonâ€™s Disease Using Metabolomic and Lipidomic Profiles from Cerebrospinal Fluid. Metabolites, 2022, 12, 277.	2.9	9
7	Serum Levels of Î±-Klotho Are Correlated with Cerebrospinal Fluid Levels and Predict Measures of Cognitive Function. Journal of Alzheimer's Disease, 2022, 86, 1471-1481.	2.6	17
8	Manifestations of Alzheimerâ€™s disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. Scientific Reports, 2022, 12, 6117.	3.3	12
9	Differential Effects of APOE Genotype on MicroRNA Cargo of Cerebrospinal Fluid Extracellular Vesicles in Females With Alzheimerâ€™s Disease Compared to Males. Frontiers in Cell and Developmental Biology, 2022, 10, 864022.	3.7	15
10	Cognition as a mediator for gait and balance impairments in GBA-related Parkinsonâ€™s disease. Npj Parkinson's Disease, 2022, 8, .	5.3	1
11	An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-Îµ4 in female patients with Alzheimerâ€™s disease. Nature Aging, 2022, 2, 616-634.	11.6	11
12	Î±â€Synuclein Seed Amplification in <scp>CSF</scp> and Brain from Patients with Different Brain Distributions of Pathological Î±â€Synuclein in the Context of Coâ€Pathology and <scp>Nonâ€LBD</scp> Diagnoses. Annals of Neurology, 2022, 92, 650-662.	5.3	19
13	Raman spectroscopy and machine learning for biomedical applications: Alzheimerâ€™s disease diagnosis based on the analysis of cerebrospinal fluid. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2021, 248, 119188.	3.9	61
14	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	9.0	144
15	Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying Î±-Synucleinâ€“Containing Extracellular Vesicles. Neurology, 2021, 96, e2332-e2345.	1.1	18
16	Loss of NRF2 accelerates cognitive decline, exacerbates mitochondrial dysfunction, and is required for the cognitive enhancing effects of Centella asiatica during aging. Neurobiology of Aging, 2021, 100, 48-58.	3.1	17
17	Prolonged Treatment with Centella asiatica Improves Memory, Reduces Amyloid-Î² Pathology, and Activates NRF2-Regulated Antioxidant Response Pathway in 5xFAD Mice. Journal of Alzheimer's Disease, 2021, 81, 1453-1468.	2.6	17
18	Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans. Movement Disorders, 2021, 36, 2094-2103.	3.9	20

#	Article	IF	Citations
19	Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinsonâ€™s disease. Journal of Clinical and Experimental Neuropsychology, 2021, 43, 469-480.	1.3	10
20	Changes in prefrontal cortical activity and turning in response to dopaminergic and cholinergic therapy in Parkinson's disease: A randomized cross-over trial. Parkinsonism and Related Disorders, 2021, 86, 10-14.	2.2	8
21	Cerebrospinal Fluid MicroRNA Changes in Cognitively Normal Veterans With a History of Deployment-Associated Mild Traumatic Brain Injury. Frontiers in Neuroscience, 2021, 15, 720778.	2.8	3
22	Gene-Specific DNA Methylation Linked to Postoperative Cognitive Dysfunction in Apolipoprotein E3 and E4 Mice. Journal of Alzheimer's Disease, 2021, 83, 1251-1268.	2.6	8
23	Peripheral Blood NRF2 Expression as a Biomarker in Human Health and Disease. Antioxidants, 2021, 10, 28.	5.1	7
24	Relationships Between Sensorimotor Inhibition and Mobility in Older Adults With and Without Parkinsonâ€™s Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 630-637.	3.6	6
25	Developing a Rational, Optimized Product of Centella asiatica for Examination in Clinical Trials: Real World Challenges. Frontiers in Nutrition, 2021, 8, 799137.	3.7	2
26	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	2.4	12
27	Centella asiatica Alters Metabolic Pathways Associated With Alzheimerâ€™s Disease in the 5xFAD Mouse Model of ÃŸ-Amyloid Accumulation. Frontiers in Pharmacology, 2021, 12, 788312.	3.5	12
28	Caffeoylquinic Acids in Centella asiatica Reverse Cognitive Deficits in Male 5XFAD Alzheimerâ€™s Disease Model Mice. Nutrients, 2020, 12, 3488.	4.1	34
29	Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntingtonâ€™s Disease Patientsâ€”A Randomized Phase 2 Clinical Trial. Journal of Clinical Medicine, 2020, 9, 3682.	2.4	15
30	Hallucinations and Development of Dementia in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 1643-1648.	2.8	7
31	Performance of Validated MicroRNA Biomarkers for Alzheimerâ€™s Disease in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 78, 245-263.	2.6	8
32	Sensorimotor Inhibition and Mobility in Genetic Subgroups of Parkinson's Disease. Frontiers in Neurology, 2020, 11, 893.	2.4	3
33	Multivariate prediction of dementia in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2020, 6, 20.	5.3	25
34	High-Density Lipoprotein Carries Markers That Track With Recovery From Stroke. Circulation Research, 2020, 127, 1274-1287.	4.5	26
35	Prefrontal Cortex Activity and Gait in Parkinson's Disease With Cholinergic and Dopaminergic Therapy. Movement Disorders, 2020, 35, 2019-2027.	3.9	25
36	Copper Modulation and Memory Impairment due to Hippocampal Tau Pathology. Journal of Alzheimer's Disease, 2020, 78, 49-60.	2.6	4

#	Article	IF	Citations
37	Oxidized Products of Omega-6 and Omega-3 Long Chain Fatty Acids Are Associated with Increased White Matter Hyperintensity and Poorer Executive Function Performance in a Cohort of Cognitively Normal Hypertensive Older Adults. Journal of Alzheimer's Disease, 2020, 74, 65-77.	2.6	25
38	Age-Associated DNA Methylation Patterns Are Shared Between the Hippocampus and Peripheral Blood Cells. Frontiers in Genetics, 2020, 11, 111.	2.3	12
39	Observation of Reduced Homeostatic Metabolic Activity and/or Coupling in White Matter Aging. Journal of Neuroimaging, 2020, 30, 658-665.	2.0	7
40	Centella asiatica Water Extract Shows Low Potential for Cytochrome P450â€“Mediated Drug Interactions. Drug Metabolism and Disposition, 2020, 48, 1053-1063.	3.3	4
41	Erythrocytic Î±-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinsonâ€™s disease pathogenesis. Acta Neuropathologica Communications, 2020, 8, 102.	5.2	26
42	Soluble TREM2 is elevated in Parkinsonâ€™s disease subgroups with increased CSF tau. Brain, 2020, 143, 932-943.	7.6	49
43	Participant and Study Partner Reported Impact of Cognition on Functional Activities in Parkinson's Disease. Movement Disorders Clinical Practice, 2020, 7, 61-69.	1.5	11
44	<scp>Openâ€Label</scp> Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2020, 7, 440-447.	1.5	34
45	Integration of mass spectral fingerprinting analysis with precursor ion (MS1) quantification for the characterisation of botanical extracts: application to extracts of <scp>Centella asiatica</scp> (L.) Urban. Phytochemical Analysis, 2020, 31, 722-738.	2.4	28
46	Effect of APOE Genotype on Plasma Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid, Arachidonic Acid, and Hippocampal Volume in the Alzheimerâ€™s Disease Cooperative Study-Sponsored DHA Clinical Trial. Journal of Alzheimer's Disease, 2020, 74, 975-990.	2.6	38
47	Multivariate Statistical Analysis of Surface Enhanced Raman Spectra of Human Serum for Alzheimerâ€™s Disease Diagnosis. Applied Sciences (Switzerland), 2019, 9, 3256.	2.5	33
48	Cognitive associations with comprehensive gait and static balance measures in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 69, 104-110.	2.2	41
49	Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures. Clinical Parkinsonism & Related Disorders, 2019, 1, 91-97.	0.9	22
50	Validation of MicroRNA Biomarkers for Alzheimerâ€™s Disease in Human Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2019, 67, 875-891.	2.6	41
51	Visuospatial functioning is associated with sleep disturbance and hallucinations in nondemented patients with Parkinsonâ€™s disease. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 803-813.	1.3	10
52	Pre-frontal Cortical Activity During Walking and Turning Is Reliable and Differentiates Across Young, Older Adults and People With Parkinson's Disease. Frontiers in Neurology, 2019, 10, 536.	2.4	47
53	Sex and genetic differences in postoperative cognitive dysfunction: a longitudinal cohort analysis. Biology of Sex Differences, 2019, 10, 14.	4.1	35
54	Randomized Trial of Marine n-3 Polyunsaturated Fatty Acids for the Prevention of Cerebral Small Vessel Disease and Inflammation in Aging (PUFA Trial): Rationale, Design and Baseline Results. Nutrients, 2019, 11, 735.	4.1	17

#	Article	IF	Citations
55	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. Cell, 2019, 177, 231-242.	28.9	152
56	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates Aî², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
57	Centella Asiatica Improves Memory and Promotes Antioxidative Signaling in 5XFAD Mice. Antioxidants, 2019, 8, 630.	5.1	47
58	Comparative sensitivity of the MoCA and Mattis Dementia Rating Scaleâ€2 in Parkinson's disease. Movement Disorders, 2019, 34, 285-291.	3.9	13
59	Analytics of Cerebrospinal Fluid MicroRNA Quantitative PCR Studies. Molecular Neurobiology, 2019, 56, 4988-4999.	4.0	0
60	The key role of T cells in Parkinson's disease pathogenesis and therapy. Parkinsonism and Related Disorders, 2019, 60, 25-31.	2.2	32
61	Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 50, 29-36.	2.2	94
62	Associations between <scp>CSF</scp> cortisol and <scp>CSF</scp> norepinephrine in cognitively normal controls and patients with amnestic <scp>MCI</scp> and <scp>AD</scp> dementia. International Journal of Geriatric Psychiatry, 2018, 33, 763-768.	2.7	22
63	Centella asiatica: phytochemistry and mechanisms of neuroprotection and cognitive enhancement. Phytochemistry Reviews, 2018, 17, 161-194.	6.5	144
64	Sex differences in the association of alcohol with cognitive decline and brain pathology in a cohort of octogenarians. Psychopharmacology, 2018, 235, 761-770.	3.1	19
65	Centella asiatica attenuates hippocampal mitochondrial dysfunction and improves memory and executive function in Î²-amyloid overexpressing mice. Molecular and Cellular Neurosciences, 2018, 93, 1-9.	2.2	53
66	Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. Journal of Clinical Lipidology, 2018, 12, 1169-1178.	1.5	83
67	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
68	Lost in Translation? Finding Our Way To Effective Alzheimerâ€™s Disease Therapies. Journal of Alzheimer's Disease, 2018, 64, S33-S39.	2.6	3
69	Centella asiatica increases hippocampal synaptic density and improves memory and executive function in aged mice. Brain and Behavior, 2018, 8, e01024.	2.2	48
70	Version 3 of the National Alzheimerâ€™s Coordinating Centerâ€™s Uniform Data Set. Alzheimer Disease and Associated Disorders, 2018, 32, 351-358.	1.3	241
71	Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid Î² 1â€“42 in CSF for the Diagnosis of Alzheimerâ€™s Disease. Journal of Proteome Research, 2017, 16, 1228-1238.	3.7	30
72	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.8	166

#	Article	IF	Citations
73	Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease. Neurobiology of Aging, 2017, 56, 211.e1-211.e7.	3.1	37
74	Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains. JAMA Neurology, 2017, 74, 91.	9.0	367
75	The effects of noncoding aquaporinâ€4 singleâ€nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 348-359.	3.7	94
76	Centella asiatica attenuates AÎ²-induced neurodegenerative spine loss and dendritic simplification. Neuroscience Letters, 2017, 646, 24-29.	2.1	34
77	An alphaâ€synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression. Proteomics - Clinical Applications, 2017, 11, 1700045.	1.6	9
78	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurology, The, 2017, 16, 55-65.	10.2	394
79	Analysis of extracellular RNA in cerebrospinal fluid. Journal of Extracellular Vesicles, 2017, 6, 1317577.	12.2	68
80	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
81	Homocysteine and cognitive function in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 44, 1-5.	2.2	44
82	Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. Annals of Clinical and Translational Neurology, 2017, 4, 15-25.	3.7	40
83	Serum Hepcidin Levels, Iron Dyshomeostasis and Cognitive Loss in Alzheimerâ€™s Disease. , 2017, 8, 215.		32
84	Centella asiatica Attenuates Mitochondrial Dysfunction and Oxidative Stress in AÎ²-Exposed Hippocampal Neurons. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-8.	4.0	34
85	Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults. Alzheimer's Research and Therapy, 2017, 9, 48.	6.2	38
86	MicroRNAs in Human Cerebrospinal Fluid as Biomarkers for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 1223-1233.	2.6	93
87	CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1125-1131.	0.8	154
88	Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiology of Aging, 2016, 41, 200.e13-200.e20.	3.1	174
89	Comment: Gene-environment interactions in dementiaâ€”. Neurology, 2016, 86, 2069-2069.	1.1	2
90	Association ofGBAMutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurology, 2016, 73, 1217.	9.0	185

#	Article	IF	Citations
91	Do Ï‰-3 Fatty Acids Regulate Cerebral Î² Amyloid?. JAMA Neurology, 2016, 73, 1183.	9.0	2
92	STX, a Novel Membrane Estrogen Receptor Ligand, Protects Against Amyloid-Î² Toxicity. Journal of Alzheimer's Disease, 2016, 51, 391-403.	2.6	20
93	The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2016, 8, 25.	6.2	55
94	Centella asiatica modulates antioxidant and mitochondrial pathways and improves cognitive function in mice. Journal of Ethnopharmacology, 2016, 180, 78-86.	4.1	84
95	Surgery is associated with ventricular enlargement as well as cognitive and functional decline. Alzheimer's and Dementia, 2016, 12, 590-597.	0.8	47
96	GBA Variants are associated with a distinct pattern of cognitive deficits in <scp>P</scp>arkinson's disease. Movement Disorders, 2016, 31, 95-102.	3.9	158
97	Precision Medicine. American Journal of Pathology, 2016, 186, 500-506.	3.8	49
98	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	7.9	260
99	Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimerâ€™s disease subjects. Acta Neuropsychiatrica, 2015, 27, 270-278.	2.1	96
100	Centella asiatica Attenuates Amyloid-Î²-Induced Oxidative Stress and Mitochondrial Dysfunction. Journal of Alzheimer's Disease, 2015, 45, 933-946.	2.6	67
101	Increased CSF E-Selectin in Clinical Alzheimerâ€™s Disease without Altered CSF AÎ² 42 and Tau. Journal of Alzheimer's Disease, 2015, 47, 883-887.	2.6	15
102	Extracellular RNAs: development as biomarkers of human disease. Journal of Extracellular Vesicles, 2015, 4, 27495.	12.2	72
103	Targeted Lipidomics of Fontal Cortex andÂPlasma Diacylglycerols (DAG) inÂMildÂCognitive Impairment and Alzheimerâ€™s Disease: Validation ofÂDAGÂAccumulation Early in the Pathophysiology of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 48, 537-546.	2.6	72
104	Rarity of the Alzheimer Diseaseâ€“ProtectiveAPPA673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	9.0	41
105	Cognitive profile of LRRK2â€related Parkinson's disease. Movement Disorders, 2015, 30, 728-733.	3.9	64
106	Diagnostic Values of Cerebrospinal Fluid T-Tau and AÎ²42 using Meso Scale Discovery Assays for Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 709-719.	2.6	28
107	Alterations in mitochondrial number and function in Alzheimerâ€™s disease fibroblasts. Metabolic Brain Disease, 2015, 30, 1275-1278.	2.9	16
108	Cerebrospinal Fluid Peptides as Potential Parkinson Disease Biomarkers: A Staged Pipeline for Discovery and Validation*. Molecular and Cellular Proteomics, 2015, 14, 544-555.	3.8	51

#	Article	IF	Citations
109	Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 692-697.	2.2	99
110	Role of soluble epoxide hydrolase in age-related vascular cognitive decline. Prostaglandins and Other Lipid Mediators, 2014, 113-115, 30-37.	1.9	52
111	People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. Movement Disorders, 2014, 29, 1258-1264.	3.9	76
112	Oral Zinc Reduces Amyloid Burden in Tg2576 Mice. Journal of Alzheimer's Disease, 2014, 41, 179-192.	2.6	35
113	Influence of Lifestyle Modifications on Age-Related Free Radical Injury to Brain. JAMA Neurology, 2014, 71, 1150.	9.0	23
114	Longitudinal relaxographic imaging of white matter hyperintensities in the elderly. Fluids and Barriers of the CNS, 2014, 11, 24.	5.0	11
115	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	9.0	166
116	Cross-Sectional and Longitudinal Relationships Between Cerebrospinal Fluid Biomarkers and Cognitive Function in People Without Cognitive Impairment From Across the Adult Life Span. JAMA Neurology, 2014, 71, 742.	9.0	40
117	APOE,MAPT, andSNCAGenes and Cognitive Performance in Parkinson Disease. JAMA Neurology, 2014, 71, 1405.	9.0	172
118	Targeted Discovery and Validation of Plasma Biomarkers of Parkinsonâ€™s Disease. Journal of Proteome Research, 2014, 13, 4535-4545.	3.7	30
119	Evaluation of mild cognitive impairment subtypes in Parkinson's disease. Movement Disorders, 2014, 29, 756-764.	3.9	53
120	Plasma exosomal Î±-synuclein is likely CNS-derived and increased in Parkinsonâ€™s disease. Acta Neuropathologica, 2014, 128, 639-650.	7.7	504
121	Association of cerebrospinal fluid AÎ²42 with A2M gene in cognitively normal subjects. Neurobiology of Aging, 2014, 35, 357-364.	3.1	6
122	Caffeoylquinic Acids in Centella asiatica Protect against Amyloid-Î² Toxicity. Journal of Alzheimer's Disease, 2014, 40, 359-373.	2.6	78
123	Modulation of tau phosphorylation by environmental copper. Translational Neurodegeneration, 2014, 3, 24.	8.0	56
124	Memory, Mood, and Vitamin D in Persons with Parkinson's Disease. Journal of Parkinson's Disease, 2013, 3, 547-555.	2.8	65
125	Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. Neurology, 2013, 81, 2024-2027.	1.1	89
126	APOE Ïµ4 Increases Risk for Dementia in Pure Synucleinopathies. JAMA Neurology, 2013, 70, 223.	9.0	302

#	Article	IF	Citations
127	A Randomized Placebo-Controlled Pilot Trial of Omega-3 Fatty Acids and Alpha Lipoic Acid in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 111-120.	2.6	210
128	The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2013, 5, 59.	6.2	80
129	Pacific Northwest Udall Center of Excellence Clinical Consortium: Study Design and Baseline Cohort Characteristics. Journal of Parkinson's Disease, 2013, 3, 205-214.	2.8	64
130	Plasma omega-3 PUFA and white matter mediated executive decline in older adults. Frontiers in Aging Neuroscience, 2013, 5, 92.	3.4	39
131	Dyslipidemia and Blood-Brain Barrier Integrity in Alzheimer's Disease. Current Gerontology and Geriatrics Research, 2012, 2012, 1-5.	1.6	63
132	Incidence of New-Onset Seizures in Mild to Moderate Alzheimer Disease. Archives of Neurology, 2012, 69, 368.	4.5	117
133	Biomarkers for Alzheimer's Disease: Showing the Way or Leading Us Astray?. Journal of Alzheimer's Disease, 2012, 33, S371-S376.	2.6	6
134	Common variation in the LRRK2 gene is a risk factor for Parkinson's disease. Movement Disorders, 2012, 27, 1823-1826.	3.9	14
135	Review of selected databases of longitudinal aging studies. Alzheimer's and Dementia, 2012, 8, 584-589.	0.8	20
136	ADAM10 expression and promoter haplotype in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 2229.e1-2229.e9.	3.1	22
137	Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology, 2012, 79, 221-228.	1.1	144
138	Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 874-883.	1.7	16
139	Serum vitamin d concentrations are associated with falling and cognitive function in older adults. Journal of Nutrition, Health and Aging, 2012, 16, 898-901.	3.3	38
140	Antioxidants for Alzheimer Disease. Archives of Neurology, 2012, 69, 836-41.	4.5	314
141	Centella asiaticaExtract Improves Behavioral Deficits in a Mouse Model of Alzheimer's Disease: Investigation of a Possible Mechanism of Action. International Journal of Alzheimer's Disease, 2012, 2012, 1-9.	2.0	77
142	The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature, 2011, 477, 90-94.	27.8	1,453
143	Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy. American Journal of Pathology, 2011, 178, 1509-1516.	3.8	97
144	Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: The case for isradipine. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1584-1590.	3.8	114

#	Article	IF	Citations
145	Gender Effects on Plasma and Brain Copper. International Journal of Alzheimer's Disease, 2011, 2011, 1-4.	2.0	17
146	Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease. PLoS ONE, 2011, 6, e16032.	2.5	152
147	Phytic Acid as a Potential Treatment for Alzheimer's Pathology: Evidence from Animal and in vitro Models. Journal of Alzheimer's Disease, 2011, 23, 21-35.	2.6	62
148	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	21.4	1,676
149	L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiology of Disease, 2011, 41, 62-70.	4.4	133
150	Increased Cerebrospinal Fluid F2-Isoprostanes are Associated with Aging and Latent Alzheimerâ€™s Disease as Identified by Biomarkers. NeuroMolecular Medicine, 2011, 13, 37-43.	3.4	65
151	Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Annals of Neurology, 2011, 69, 570-580.	5.3	371
152	Modeling of Pathological Traits in Alzheimer's Disease Based on Systemic Extracellular Signaling Proteome. Molecular and Cellular Proteomics, 2011, 10, M111.008862.	3.8	40
153	The Blood-Brain Barrier and Microvascular Water Exchange in Alzheimer's Disease. Cardiovascular Psychiatry and Neurology, 2011, 2011, 1-9.	0.8	23
154	Reliability and Validity of Food Frequency Questionnaire and Nutrient Biomarkers in Elders With and Without Mild Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2011, 25, 49-57.	1.3	43
155	A translational continuum of model systems for evaluating treatment strategies in Alzheimerâ€™s disease: isradipine as a candidate drug. DMM Disease Models and Mechanisms, 2011, 4, 634-648.	2.4	39
156	Aberrant Detergent-Insoluble Excitatory Amino Acid Transporter 2 Accumulates in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2010, 69, 667-676.	1.7	59
157	Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment and Dementia. Journal of Alzheimer's Disease, 2010, 19, 301-309.	2.6	17
158	Uric Acid as a CNS Antioxidant. Journal of Alzheimer's Disease, 2010, 19, 1331-1336.	2.6	197
159	CSF AÎ²₄₂ and tau in Parkinson's disease with cognitive impairment. Movement Disorders, 2010, 25, 2682-2685.	3.9	162
160	A Copper-Lowering Strategy Attenuates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 21, 903-914.	2.6	30
161	Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease. JAMA - Journal of the American Medical Association, 2010, 304, 1903.	7.4	626
162	SNCA Variant Associated With Parkinson Disease and Plasma Î±-Synuclein Level. Archives of Neurology, 2010, 67, 1350-6.	4.5	157

#	Article	IF	Citations
163	YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease. Biological Psychiatry, 2010, 68, 903-912.	1.3	382
164	DJ-1 and Î±-synuclein in human cerebrospinal fluid as biomarkers of Parkinsonâ€™s disease. Brain, 2010, 133, 713-726.	7.6	575
165	Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neuroscience Letters, 2010, 480, 78-82.	2.1	184
166	CCR6: A Biomarker for Alzheimer's-like Disease in a Triple Transgenic Mouse Model. Journal of Alzheimer's Disease, 2010, 22, 619-629.	2.6	44
167	Failure of Biomarkers in Clinical Trials of Alzheimer's Disease: Blaming the Messenger?. Journal of Alzheimer's Disease, 2009, 18, 103-104.	2.6	0
168	Ascorbic Acid and Rates of Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 93-98.	2.6	75
169	Copper in Alzheimerâ€™s disease: too much or too little?. Expert Review of Neurotherapeutics, 2009, 9, 631-637.	2.8	36
170	Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12145-12150.	7.1	171
171	Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimer's and Dementia, 2009, 5, 18-29.	0.8	322
172	MRI Substudy Participation in Alzheimer Disease (AD) Clinical Trials. Alzheimer Disease and Associated Disorders, 2009, 23, 333-336.	1.3	4
173	Relapsing polychondritis: an uncommon cause of dementia. BMJ Case Reports, 2009, 2009, bcr0820080740-bcr0820080740.	0.5	3
174	Cognitive impairment and dementia in patients with Parkinson disease. Current Topics in Medicinal Chemistry, 2009, 9, 903-12.	2.1	58
175	Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radical Biology and Medicine, 2008, 45, 219-230.	2.9	95
176	Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurology, The, 2008, 7, 704-714.	10.2	85
177	Application of Targeted Quantitative Proteomics Analysis in Human Cerebrospinal Fluid Using a Liquid Chromatography Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Tandem Mass Spectrometer (LC MALDI TOF/TOF) Platform. Journal of Proteome Research, 2008, 7, 720-730.	3.7	67
178	Phase 2 Safety Trial Targeting Amyloid Î² Production With a Î³-Secretase Inhibitor in Alzheimer Disease. Archives of Neurology, 2008, 65, 1031-8.	4.5	298
179	Detecting Alzheimer disease before it happens. Neurology, 2008, 71, 78-79.	1.1	4
180	CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases. American Journal of Clinical Pathology, 2008, 129, 526-529.	0.7	248

#	Article	IF	Citations
181	Alzheimerâ€™s disease and the bloodâ€“brain barrier: past, present and future. Aging Health, 2008, 4, 47-57.	0.3	38
182	Evaluation of Coenzyme Q as an Antioxidant Strategy for Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 225-234.	2.6	92
183	Nutritional Biomarkers in Alzheimer's Disease: The Association between Carotenoids, n-3 Fatty Acids, and Dementia Severity. Journal of Alzheimer's Disease, 2008, 13, 31-38.	2.6	103
184	Multiple SNPs Within and Surrounding the Apolipoprotein E Gene Influence Cerebrospinal Fluid Apolipoprotein E Protein Levels. Journal of Alzheimer's Disease, 2008, 13, 255-266.	2.6	75
185	Chronic dietary Î±-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiology of Aging, 2007, 28, 213-225.	3.1	155
186	A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics, 2007, 7, 469-473.	2.2	111
187	Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Medicine, 2007, 13, 1359-1362.	30.7	969
188	F2-Isoprostanes as Biomarkers of Late-onset Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2007, 33, 114-119.	2.3	60
189	Identification of Glycoproteins in Human Cerebrospinal Fluid with a Complementary Proteomic Approach. Journal of Proteome Research, 2006, 5, 2769-2779.	3.7	88
190	Mitochondria are a direct site of AÎ² accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Human Molecular Genetics, 2006, 15, 1437-1449.	2.9	996
191	Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 8, 359-367.	2.6	20
192	Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. Journal of Alzheimer's Disease, 2006, 9, 293-348.	2.6	362
193	Age and Apolipoprotein E*4 Allele Effects on Cerebrospinal Fluid Î²-Amyloid 42 in Adults With Normal Cognition. Archives of Neurology, 2006, 63, 936.	4.5	118
194	Safety and Acceptability of the Research Lumbar Puncture. Alzheimer Disease and Associated Disorders, 2005, 19, 220-225.	1.3	170
195	Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. Journal of Alzheimer's Disease, 2005, 7, 125-133.	2.6	160
196	Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Research, 2005, 1037, 209-213.	2.2	100
197	Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro. Journal of Neuroscience Research, 2005, 80, 406-413.	2.9	51
198	Proteomic determination of widespread detergent insolubility, including AÎ² but not tau, early in the pathogenesis of Alzheimer's disease. FASEB Journal, 2005, 19, 1923-1925.	0.5	46

#	Article	IF	Citations
199	F₂-Isoprostanes in Alzheimer and Other Neurodegenerative Diseases. Antioxidants and Redox Signaling, 2005, 7, 269-275.	5.4	106
200	Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiology of Aging, 2005, 26, 207-227.	3.1	162
201	apoE isoforms and measures of anxiety in probable AD patients and Apoeâ^'/â^' mice. Neurobiology of Aging, 2005, 26, 637-643.	3.1	69
202	F2-Isoprostanes as Biomarkers of Late Onset Alzheimerâ€™s Disease. Oxidative Stress and Disease, 2005, , 147-157.	0.3	0
203	Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Human Molecular Genetics, 2004, 13, 1225-1240.	2.9	309
204	Phytochemicals in Alzheimer Disease: The Development of Clinical Trials. Pharmaceutical Biology, 2004, 42, 64-73.	2.9	7
205	Phytochemicals in Alzheimer Disease: The Development of Clinical Trials. Archives of Physiology and Biochemistry, 2004, 42, 64-73.	2.1	0
206	Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chemistry and Physics of Lipids, 2004, 128, 117-124.	3.2	222
207	Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. Journal of Alzheimer's Disease, 2004, 6, 93-97.	2.6	88
208	Measurement of Gelatinase B (MMP-9) in the Cerebrospinal Fluid of Patients With Vascular Dementia and Alzheimer Disease. Stroke, 2004, 35, e159-62.	2.0	124
209	Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. Journal of Neuroimmunology, 2003, 137, 32-41.	2.3	117
210	Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Experimental Neurology, 2003, 184, 510-520.	4.1	202
211	Cerebrospinal Fluid Tau and Î²-Amyloid. Archives of Neurology, 2003, 60, 1696.	4.5	341
212	Antioxidants in Alzheimer's disease-vitamin C delivery to a demanding brain. Journal of Alzheimer's Disease, 2003, 5, 309-313.	2.6	50
213	Vascular Dementia. Journal of the American Medical Directors Association, 2003, 4, S155-S161.	2.5	3
214	Mouse cerebral prostaglandins, but not oxidative damage, change with age and are responsive to indomethacin treatment. Brain Research, 2002, 930, 75-82.	2.2	14
215	Lipid peroxidation in aging brain and Alzheimerâ€™s disease1,2 1Guest Editors: Mark A. Smith and George Perry 2This article is part of a series of reviews on â€œCauses and Consequences of Oxidative Stress in Alzheimerâ€™s Disease.â€•The full list of papers may be found on the homepage of the journal.. Free Radical Biology and Medicine, 2002, 33, 620-626.	2.9	406
216	Peripheral F₂â€isoprostanes and F₄â€neuroprostanes are not increased in Alzheimer's disease. Annals of Neurology, 2002, 52, 175-179.	5.3	156

#	Article	IF	Citations
217	Î²-Amyloid Plaques Induce Neuritic Dystrophy of Nitric Oxide-Producing Neurons in a Transgenic Mouse Model of Alzheimer's Disease. Experimental Neurology, 2001, 168, 203-212.	4.1	24
218	Cerebrospinal Fluid AÎ²42, Tau, and F2-Isoprostane Concentrations in Patients With Alzheimer Disease, Other Dementias, and in Age-Matched Controls. Archives of Pathology and Laboratory Medicine, 2001, 125, 510-512.	2.5	106
219	Open label tissue plasminogen activator for stroke: The Oregon experience. Journal of Stroke and Cerebrovascular Diseases, 1999, 8, 287-290.	1.6	21
220	Novel antigenic determinant expressed in neurons of the dorsolateral hypothalamus in rat and human. Journal of Neuroscience Research, 1992, 31, 715-723.	2.9	1
221	An anatomical study of cholinergic innervation in rat cerebral cortex. Neuroscience, 1988, 25, 457-474.	2.3	391